Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
TrovaGene (NASDAQ:TROV) reported quarterly losses of $(0.410) per share. This is a 59.8 percent increase over losses of $(1.020...
Gainers • Chimerix, Inc. (NASDAQ:CMRX) shares increased by 38.41% to $2.09 during Wednesday's pre-market session. • Accur...
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the grea...
On April 15, 2020, Trovagene, Inc. (the “Company”) was granted a loan (the “Loan”) from JPMorgan Chase Bank, N.A. in the aggreg...
